8-Kfiled August 26, 2021, 7:59 PM ETticker ARCTCIK 0001768224
other materialconfidence highsentiment neutralmateriality 0.50
Arcturus terminates Providence joint venture; director resigns after Ultragenyx ownership drop
Arcturus Therapeutics Holdings Inc.
On Aug 20, 2021, Arcturus received notice from Providence to terminate the Amended and Restated Joint Venture, Research Collaboration and License Agreement; no termination penalties incurred.
On Aug 25, 2021, director Karah Parschauer resigned from the board effective same day.
Parschauer was Ultragenyx's nominee; her departure follows Ultragenyx's stock sales reducing its ownership below the contractual threshold.
Company continues collaboration with Ultragenyx; board will remain at six members until a replacement is identified.
On August 25, 2021, Karah Parschauer notified the board of directors (the “Board”) of Arcturus Therapeutics Holdings Inc. (the “Company”) of her resignation from the Board and any associated committees of the Board, effective August 25, 2021.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Karah Parschauer resigned as Director at Arcturus Therapeutics Holdings Inc..
Action
resigned
Role
Director
Exact text from the filing
On August 25, 2021, Karah Parschauer notified the board of directors (the “Board”) of Arcturus Therapeutics Holdings Inc. (the “Company”) of her resignation from the Board and any associated committees of the Board, effective August 25, 2021.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.